Important announcement concerning Temple Health and Keystone First. Our provider agreement with Keystone First, is scheduled to end on July 31st. Learn about your options to continue receiving care at Temple Health.
Breadcrumb
- Home
- About Us
- R&D Alliances
- Technology Transfer
- Technology Licensing
- COVID Therapeutics and Diagnostics
COVID Therapeutics and Diagnostics
(technologies available for licensing)
Note: Links to Patents may require a browser newer than Internet Explorer 9, such as Chrome, Safari, Firefox, Edge, or Internet Explorer 11TECH ID | TITLE | LEAD INVENTOR | CONTACT |
---|---|---|---|
559-RD |
Novel Therapeutic Antibodies for SARS-CoV-2 Virus and Variants. Patent pending. |
FDA, JHU and FCCC (Roland Dunbrack) |
Share
-
Share with Facebook
-
Share with twitter
-
Share with email
-
Print this